MG115|CAS 133407-86-0|DC Chemicals

Cas No.:	133407-86-0
Chemical Name:	MG-115
Synonyms:	L-Leucinamide,N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formylbutyl]-;(S)-MG115;MG-115;MG-115 (Z-LL-Nva-CHO);Z-Leu-Leu-Norvalinal;benzyl N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxopentan-2-yl]amino]pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate;MG115 Z-LLnV;MG115;Z-LLnV;Z-LL-NVA-CHO;Z-LEU-LEU-NVA-H;Z-LEU-LEU-NVA-CHO;Z-LEU-LEU-NVA-ALDEHYDE;N-CBZ-LEU-LEU-NORVALINAL;MG115, Z-LLnV;N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxopentan-2-yl]amino]pentan-2-yl]amino]-1-oxopentan-2-yl]carbamic acid (phenylmethyl) ester;CHEBI:95100;GTPL11639;Cbz-Leu-Leu-norvalinal;CS-0029136;Q27166869;carbobenzoxy-leucyl-leucyl-norvalinal;Curator_000004;EX-A1500B;Carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal;DTXSID00432100;J-006370;AKOS040744889;HY-108552;CHEMBL4518490;SCHEMBL2140161;n-benzyloxycarbonyl-l-leucyl-l-leucyl-l-norvalinal;133407-86-0;NCGC00345815-01;Z-Leu-Leu-Norvalinal, >=90% (HPLC), powder;BDBM476985;QEJRGURBLQWEOU-FKBYEOEOSA-N;DA-55451;DTXCID50382929;benzyl N-((2S)-4-methyl-1-(((2S)-4-methyl-1-oxo-1-(((2S)-1-oxopentan-2-yl)amino)pentan-2-yl)amino)-1-oxopentan-2-yl)carbamate;G12577
SMILES:	O=C([C@H](CC(C)C)NC(=O)OCC1C=CC=CC=1)N[C@H](C(N[C@H](C=O)CCC)=O)CC(C)C
Formula:	C₂₅H₃₉N₃O₅
M.Wt:	461.594267129898
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Rock KL, et, al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761-71. [2]. Lopes UG, et, al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997 May 16;272(20):12893-6. [3]. Kim J, et, al. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther. 2005 Nov;12(21):1581-90.

Target:	Ki: 21 nM (20S proteasome); 35 nM (26 Sproteasome)[1]
In Vitro:	MG-115 (0.1-10 μM; 24 h) dose-dependently decreases the viability of HepG2 cells[3]. MG-115 (0.1-10 μM; 24 h) amplifies the reporter gene expression mediated by CWK18 DNA condensates[3]. Cell Viability Assay[3] Cell Line: HepG2 cells Concentration: 0.1, 1, 2, 5, 10 μM Incubation Time: 24 hours Result: Dose-dependently decreased cell viability. Inhibited the proteasomal activity, with an IC50 of 2 μM.
References:	[1]. Rock KL, et, al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994 Sep 9;78(5):761-71. [2]. Lopes UG, et, al. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997 May 16;272(20):12893-6. [3]. Kim J, et, al. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther. 2005 Nov;12(21):1581-90.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.